Aduro Biotech Inc (ADRO)

10.15
NASDAQ : Health Care
Prev Close 10.35
Day Low/High 10.00 / 10.40
52 Wk Low/High 7.26 / 16.43
Avg Volume 292.90K
Exchange NASDAQ
Shares Outstanding 68.00M
Market Cap 703.78M
EPS -1.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

3 Stocks Setting Up for Major Breakouts

3 Stocks Setting Up for Major Breakouts

Here's how to rake in the gains off some potential major breakouts.

Commit To Purchase Aduro Biotech At $7.50, Earn 20.8% Annualized Using Options

Commit To Purchase Aduro Biotech At $7.50, Earn 20.8% Annualized Using Options

Investors considering a purchase of Aduro Biotech Inc shares, but cautious about paying the going market price of $10.28/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the July 2017 put at the $7.50 strike, which has a bid at the time of this writing of 90 cents.

Trump's Drug Pricing Comment Sends Biotech Stocks Into Free-Fall

Trump's Drug Pricing Comment Sends Biotech Stocks Into Free-Fall

There's little to substantiate the president-elect's claim that he will bring drug prices down, but biotech investors are trading anyway.

Aduro Biotech Presents Preclinical Data Supporting Clinical Development Of Its Anti-APRIL Antibody, BION-1301, For The Treatment Of Multiple Myeloma

Aduro Biotech Presents Preclinical Data Supporting Clinical Development Of Its Anti-APRIL Antibody, BION-1301, For The Treatment Of Multiple Myeloma

Poster #2112 to be Presented at the 58th American Society of Hematology Annual Meeting and Exposition

Partial Clinical Hold Lifted And Enrollment Resumes For Aduro Biotech LADD Clinical Trials

Partial Clinical Hold Lifted And Enrollment Resumes For Aduro Biotech LADD Clinical Trials

Company's Ongoing Clinical Trials with LADD-based Therapies Include Mesothelioma and Ovarian Cancers as well as Personalized LADD (pLADD)

Aduro Biotech's Personalized LADD Therapy Featured In An Oral Presentation At SITC's New Cancer Immunotherapy Agents In Development Program

Aduro Biotech's Personalized LADD Therapy Featured In An Oral Presentation At SITC's New Cancer Immunotherapy Agents In Development Program

-- Personalized LADD, or pLADD, is being developed utilizing patient-specific neoantigens --

Aduro Biotech Presents Preclinical Data Demonstrating Acute And Systemic Immune Activation Through STING Pathway Stimulation With ADU-S100

Aduro Biotech Presents Preclinical Data Demonstrating Acute And Systemic Immune Activation Through STING Pathway Stimulation With ADU-S100

Combination of ADU-S100 and PD-1 Blockade Resulted in Complete Eradication of Local and Distal Tumors

Aduro Biotech Enters Oversold Territory (ADRO)

Aduro Biotech Enters Oversold Territory (ADRO)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Aduro Biotech To Host Conference Call

Aduro Biotech To Host Conference Call

Aduro Biotech Enters Oversold Territory (ADRO)

Aduro Biotech Enters Oversold Territory (ADRO)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week of ADRO November 18th Options Trading

First Week of ADRO November 18th Options Trading

Investors in Aduro Biotech Inc saw new options begin trading this week, for the November 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ADRO options chain for the new November 18th contracts and identified one put and one call contract of particular interest.